Glide raises £3.2m for solid dose injector programme
Oxford, UK-based Glide Technologies has raised £3.2 million to help it progress development of a novel solid dose formulation of osteoporosis drug teriparatide (parathyroid hormone).
Read More
Tag: SDI
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
